Net Cash Provided by (Used in) Financing Activities of Lipocine Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Lipocine Inc. annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • Lipocine Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2024 was $8,100.
  • Lipocine Inc. annual Net Cash Provided by (Used in) Financing Activities for 2025 was $2,869,552, a 1271% increase from 2024.
  • Lipocine Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $209,340, a 48% decline from 2023.
  • Lipocine Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $404,567.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

Lipocine Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,869,552 +$2,660,212 +1271% 01 Jan 2025 31 Dec 2025 10-K 10 Mar 2026 2025 FY
2024 $209,340 -$195,227 -48% 01 Jan 2024 31 Dec 2024 10-K 10 Mar 2026 2025 FY
2023 $404,567 +$2,531,511 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025 2024 FY
2022 $2,126,944 -$29,051,814 -108% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2024 2023 FY
2021 $26,924,870 +$6,025,616 +29% 01 Jan 2021 31 Dec 2021 10-K 10 Mar 2023 2022 FY
2020 $20,899,254 +$10,580,280 +103% 01 Jan 2020 31 Dec 2020 10-K 09 Mar 2022 2021 FY
2019 $10,318,974 -$333,360 -3.1% 01 Jan 2019 31 Dec 2019 10-K 11 Mar 2021 2020 FY
2018 $10,652,334 -$573,694 -5.1% 01 Jan 2018 31 Dec 2018 10-K 13 Mar 2020 2019 FY
2017 $11,226,028 +$10,620,158 +1753% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 $605,870 -$32,110,437 -98% 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
2015 $32,716,307 01 Jan 2015 31 Dec 2015 10-K 12 Mar 2018 2017 FY
2013 $48,476,246 +$48,476,246 01 Jan 2013 31 Dec 2013 10-K 31 Mar 2014 2013 FY
2012 $0 -$30,238 -100% 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2014 2013 FY
2011 $30,238 01 Jan 2011 31 Dec 2011 10-K 26 Feb 2013 2012 FY

Lipocine Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $8,100 -$2,084 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q1 2023 $6,016* +$621,330 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $627,346 -$30,067,553 -102% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q1 2021 $29,440,207 +$24,559,900 +503% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q1 2020 $4,880,307 -$349,574 -6.7% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q1 2019 $5,229,881 -$4,770,119 -48% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $10,000,000 +$6,913,351 +224% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q1 2017 $3,086,649 01 Jan 2017 31 Mar 2017 10-Q 07 May 2018 2018 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.